Hikma Pharmaceuticals Plc Hikma launches caffeine citrate injection
May 12 2015 - 4:00AM
RNS Non-Regulatory
TIDMHIK
Hikma Pharmaceuticals Plc
12 May 2015
PRESS RELEASE
Hikma launches caffeine citrate injection, commercialising the
first of the Bedford products
London, 12 May 2015 - Hikma Pharmaceuticals PLC ("Hikma") (LSE:
HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the fast growing
multinational pharmaceutical group, today announces it has launched
CAFCIT(R) Injection (caffeine citrate injection, USP) 60mg/3mL
(20mg/mL). CAFCIT(R) is indicated for the short-term treatment of
apnea of prematurity in infants between 28 and 33 weeks gestational
age.
Said Darwazah, Chairman and CEO of Hikma said, "This is our
first launch from the Bedford portfolio acquired last year. We are
making good progress in the transfer of the Bedford products to our
manufacturing facilities and this launch demonstrates our strong
R&D, regulatory and manufacturing capabilities."
According to IMS Health, sales of caffeine citrate injection in
the US market were approximately $7.6 million for the 12 months
ending March 2015.
-- ENDS --
Enquiries
Hikma Pharmaceuticals PLC
Susan Ringdal, VP Corporate Strategy and Investor Relations +44
(0)20 7399 2760/ +44 7776 477050
Lucinda Henderson, Deputy Head of Investor Relations +44 (0)20
7399 2765/ +44 7818 060211
Zeena Murad, Investor Relations Manager +44 (0)20 7399 2768/ +44
7771 665277
FTI Consulting
Ben Atwell/ Matthew Cole +44 (0)20 3727 1000
About Hikma
Hikma Pharmaceuticals PLC is a fast growing multinational group
focused on developing, manufacturing and marketing a broad range of
both branded and non-branded generic and in-licensed products.
Hikma operates through three businesses: "Injectables", "Branded"
and "Generics", based principally in the United States, the Middle
East and North Africa ("MENA") and Europe. In 2014, Hikma achieved
revenues of $1,489 million and profit attributable to shareholders
of $299 million.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAUAOWRVOAVAAR
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024